What peptide products does Thinheal supply?

Thinheal supplies generic peptide APIs, therapeutic peptides including GLP-1 and GLP-2 analogues, other gastrointestinal peptides, other therapeutic peptide APIs and cosmetic peptides, plus custom peptide R&D and CDMO manufacturing.

Does Thinheal offer custom peptide synthesis and CDMO services?

Yes. The CDMO business covers project-based contract research and development, contract manufacturing and commercial supply, from route design and process optimization to scale-up of peptide APIs and support toward formulations.

What production capacity does Thinheal have?

Thinheal operates an R&D center and a production base. Total capacity for chemically synthesized peptides has reached a multi-ton level, placing the company among the leading peptide producers in its segment.

Which quality documents can buyers request?

Buyers can request batch-specific Certificates of Analysis with HPLC purity and mass spectrometry identity data, and discuss additional documentation such as specifications, stability information and regulatory support files with the sales team for each project.

How can international buyers get the latest product catalog?

Use the Request a Catalog page or contact the regional desk for the USA and Europe, Russia and CIS, Asia, or the Middle East and East Asia by email, phone or WhatsApp.

High-Quality Thymalin CAS：63958-90-7 Manufacturers, Service

1 / 1

High-Quality Thymalin CAS：63958-90-7 Manufacturers, Service

Thymalin is a thymus-derived polypeptide (composed of 5 amino acids) initially isolated from bovine thymus extract. As a synthetic analog of thymic hormones, it plays a crucial role in regulating the immune system, enhancing immune function by promoting the maturation, differentiation, and function of T lymphocytes. Clinically, it is primarily used to treat immunodeficiency states, infectious diseases, and diseases associated with weakened immune function.

Send Inquiry

Product Description

Therapeutic Areas

Human Nervous System Connection

Vasopressin and cardiovascular regulation

Immunodeficiency Diseases

Used for congenital or acquired immunodeficiency, such as recurrent infections or postoperative immunodeficiency states.

Infectious Diseases

Serves as adjunct therapy for chronic viral infections (such as hepatitis B and HPV infection), bacterial infections, and tuberculosis.

Supportive Care for Tumors

Functions as an immunomodulator after radiotherapy and chemotherapy to reduce immunosuppression and improve quality of life.

Age-Related Immune Decline

Helps alleviate age-related thymic atrophy and counteracts the gradual reduction in immune function.

Autoimmune Diseases

Use with caution: Selected studies have explored its role in balancing the immune response, but potential risks should be noted.

Outlook & Development

R&D Trends

Combination therapy: Used in combination with vaccines, antiviral drugs, or tumor immunotherapy to enhance overall efficacy.
Novel delivery systems: Researching nanocarriers or long-acting formulations to improve bioavailability.

Market Potential

Growing demand: With an aging population and increasing demand for immunotherapy, thymopeptides maintain a stable market in supportive cancer care and infection management.
Regulatory status: Included in clinical guidelines in countries like Russia and China, while regulatory approvals in Europe and the United States remain limited.

Challenges & Limitations

Mechanism of action: Multi-target characteristics mean that the precise mechanism requires further elucidation.
Level of evidence: Clinical data for specific indications still lacks support from large-scale randomized controlled trials.
Competitive pressure: Novel immunomodulators (such as PD-1 inhibitors) may limit traditional application scope.

Future Direction

Precision medicine: Screening specific responders using targeted biomarkers to optimize treatment strategies.
Anti-aging research: Exploring direct therapeutic potential in reversing immunosenescence.

Conclusion

Thymalin, as a classic immunomodulator, retains measurable value in specific clinical scenarios. Nonetheless, higher-quality clinical studies remain essential to validate its full efficacy profile, and its indications should be expanded through modern technological delivery improvements and strategic combination therapies. In the future, it holds key promise in immune repair for aging populations as well as adjunctive application alongside anti-tumor treatments.

Frequently Asked Questions

What is Thymalin and what is its primary biological role?

Thymalin is a synthetic polypeptide analog composed of 5 amino acids, initially derived from bovine thymus extract. It regulates the immune system by stimulating the maturation, differentiation, and operational capacity of T lymphocytes.

What are the key clinical indications for Thymalin therapy?

Clinically, Thymalin is primarily used for immunodeficiency states (both congenital and acquired), chronic infectious diseases (such as tuberculosis, hepatitis B, and HPV), supportive post-chemotherapy and post-radiotherapy care in cancer patients, and age-related immune decline.

Can Thymalin be used safely in patients with autoimmune disorders?

Thymalin must be used with caution in autoimmune cases. While a limited number of studies have investigated its potential to balance overall immune response, potential immunological risks have been noted.

In which regions is Thymalin recognized or clinically approved?

Thymalin has been formally incorporated into clinical treatment guidelines in countries such as Russia and China. However, regulatory approvals and adoption remain limited across Western Europe and the United States.

What are the main scientific challenges currently facing Thymalin?

Its multi-target nature means its exact cellular mechanisms are not yet fully elucidated. Additionally, there is a relative lack of large-scale randomized controlled trials (RCTs), alongside competitive pressure from modern targeted biologics like PD-1 inhibitors.

What future therapeutic directions are being investigated for Thymalin?

Current research explores innovative delivery systems like nanocarriers, precision patient screening via biological markers, combinations with standard cancer immunotherapy, and its potential in reversing immunosenescence (age-related immune decline).